Crystalline forms of an antiviral compound
Crystalline forms of the anti-HCV compound (1aR,5S,8S,9S,10R,22aR)-5-tert-butyl-N-[(1R,2R)-2-(difluoromethyl)-1-{[(1-methylcyclopropyl)sulfonyl]carbamoyl}cyclopropyl]-9-ethyl-18,18-difluoro-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the crystalline forms.
1. A crystalline form of compound I:
wherein, the crystalline form is:
an ethyl acetate solvate (Compound I Form II) characterized by an X-ray powder diffractogram comprising peaks (±0.2°) at 8.7, 13.0, and 17.4°2θ as determined on a diffractometer using Cu-Kα radiation.
2. Compound I Form II according to claim 1 , further comprising:
i) a peak at 15.4°±2θ±0.2°;
ii) a diffractogram substantially as shown in FIG. 6 ;
iii) a differential scanning calorimetry (DSC) curve substantially as shown in FIG. 7 ;
iv) thermogravimetric analysis (TGA) comprising a thermogram substantially as shown in FIG. 8 ;
v) a nuclear magnetic resonance spectrum ( 1 H NMR) substantially as shown in FIG. 9 ;
vi) a dynamic vapor sorption (DVS) curve substantially as shown in FIG. 10 ; or
vii) about 1 mole equivalents of ethyl acetate.
3. A pharmaceutical composition comprising a compound according to claim 1 , and a pharmaceutically acceptable excipient.